Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • Latest News
    • Povidone-iodine...

    Povidone-iodine beneficial for viral conjunctivitis patients

    Written by Medha Baranwal Baranwal Published On 2019-10-27T19:15:32+05:30  |  Updated On 23 Aug 2021 11:57 AM GMT

    A single dose of 5% povidone-iodine improved signs and symptoms in people with adenoviral conjunctivitis and also decreased viral titers, according to a recent study presented at the American Academy of Optometry meeting.


    According to Mayo Clinic, conjunctivitis is an inflammation or infection of the transparent membrane (conjunctiva) that lines the eyelid and covers the white part of your eyeball. When small blood vessels in the conjunctiva become inflamed, they're more visible.


    Tammy Than, OD, FAAO, and colleagues conducted this Reducing Adenoviral Patient-Infected Days (RAPID) study -- a double-masked pilot trial in which 56 patients from nine centres who tested positive on an adenoviral immunoassay test (Quidel) and had symptoms for at least 4 days were randomized to receive one in-office dose of either PVP-I or artificial tears. The patients were then evaluated at day 1 or 2, 4, 7, 14 and 21 for clinical signs and self-reported symptoms and conjunctival swab sample was collected for qPCR and IL-8 assays.


    Also Read: PVP-I/dexamethasone OS Effective for Treatment of Adenoviral Conjunctivitis- Phase 2 Trial


    Key findings of the study include:

    • Fifty percent of patients that tested positive for the point of care test had confirmed PCR viral titers. Of those 28, 16 had been randomized to receive PVP-I and 12 had been randomized to receive artificial tears.

    • At day 4, adenoviral titers in the PVP-I group decreased to 2.5%, while in the artificial tears group they decreased to 14.4%.

    • The patients that received PVP-I felt better at day 4.

    • Patients given PVP-I reported that eyelid swelling, tearing, redness, eyelash matting and overall discomfort were significantly lower than in the control group.


    Also Read: Recurrent Conjunctivitis which ultimately turned out to be MDR-TB


    "We found that [PVP-I] was well tolerated," Than said, "and found at day 4, we see a trending down of the viral titers and patients feel and look better."


    More Information:

    Than T, et al. Efficacy of single administration of 5% povidone-iodine in the treatment of adenoviral conjunctivitis. Presented at: American Academy of Optometry meeting; Orlando, Fla. October 23-27, 2019.

    5% povidone-iodine adenoviral conjunctivitis American Academy of Optometry meeting conjunctivitis Medical news povidone iodine recent medical news Tammy Than viral titers 
    Source : American Academy of Optometry meeting

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medha Baranwal Baranwal
    Medha Baranwal Baranwal
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier

      This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:

      Search only trustworthy HONcode health websites:

      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      X